M
Mark Kipnes
Publications - 11
Citations - 1047
Mark Kipnes is an academic researcher. The author has contributed to research in topics: Type 2 diabetes & Tolerability. The author has an hindex of 9, co-authored 11 publications receiving 885 citations.
Papers
More filters
Journal ArticleDOI
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes
Gary A. Herman,Arthur J. Bergman,Catherine Stevens,Paul Kotey,Bingming Yi,Peng Zhao,Bruno Dietrich,George Golor,Andreas Schrodter,Bart Keymeulen,Kenneth C. Lasseter,Mark Kipnes,Karen Snyder,Deborah Hilliard,Michael Tanen,Caroline Cilissen,Marina De Smet,Inge De Lepeleire,Kristien Van Dyck,Amy Qiu Wang,Wei Zeng,Michael J. Davies,Wesley Tanaka,Jens J. Holst,Carolyn F. Deacon,Keith Gottesdiener,John A. Wagner +26 more
TL;DR: In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.
Journal ArticleDOI
New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men
Christina Wang,Ronald S. Swerdloff,Mark Kipnes,Alvin M. Matsumoto,Adrian S. Dobs,Glenn R. Cunningham,Laurence Katznelson,Thomas Weber,Theodore C. Friedman,Peter J. Snyder,Howard L. Levine +10 more
TL;DR: The T buccal system is a novel T formulation that offers a safe, effective, and convenient alternative to existing formulations for physiological T replacement therapy in hypogonadal men.
Journal ArticleDOI
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
TL;DR: Co-administration of sitagliptin and metformin was generally well tolerated in patients with type 2 diabetes and did not meaningfully alter the steady-state pharmacokinetics of either agent.
Journal ArticleDOI
Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency
Jose M. Garcia,Ronald S. Swerdloff,Christina Wang,M. Kyle,Mark Kipnes,Beverly M. K. Biller,David M. Cook,Kevin C.J. Yuen,Vivien Bonert,Adrian S. Dobs,Mark E. Molitch,George R. Merriam +11 more
TL;DR: Oral macimorelin is safe, convenient, and effective in diagnosing AGHD with accuracy comparable with the arginine+GHRH test.
Journal ArticleDOI
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Anders L. Carlson,Jennifer L. Sherr,Dorothy I. Shulman,Satish K. Garg,Rodica Pop-Busui,Bruce W. Bode,David R. Lilenquist,Ron Brazg,Kevin B. Kaiserman,Mark Kipnes,James Thrasher,John C. Reed,Robert H. Slover,Athena Philis-Tsimikas,Mark P. Christiansen,Benyamin Grosman,Anirban Roy,Melissa Vella,Richard A.M. Jonkers,Xiaoxiao Chen,John H. Shin,Toni L. Cordero,Scott W. Lee,Andrew S. Rhinehart,Robert A. Vigersky +24 more
TL;DR: In this paper, the safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) was evaluated.